Diabetes, Vol 46, Issue 3 481-487, Copyright © 1997 by American Diabetes Association

ARTICLES

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment

P Rossing, L Tarnow, S Boelskifte, BR Jensen, FS Nielsen and HH Parving
Steno Diabetes Center, Gentofte, Denmark. prossing@inet.uni-c.dk

Our objective was to compare the effect of a long-acting calcium antagonist (nisoldipine) versus an ACE inhibitor (lisinopril) on albuminuria, arterial blood pressure, and glomerular filtration rate (GFR) in hypertensive IDDM patients with diabetic nephropathy. We performed a 1-year, double-blind, double-dummy, randomized, controlled study comparing nisoldipine (20-40 mg once daily) with lisinopril (10-20 mg once daily) in 52 hypertensive IDDM subjects with diabetic nephropathy. Three patients dropped out, and results for the remaining 49 (25 nisoldipine, 24 lisinopril) are presented. Diuretics were required in 10 nisoldipine- and 8 lisinopril-treated patients. Every 3 months, 24-h ambulatory blood pressure (TM2420, A&D, Tokyo, Japan) and albuminuria in three 24-h samples (enzyme immunoassay) were measured; GFR (51Cr-EDTA plasma clearance) was recorded every 6 months. Mean arterial blood pressure (24 h) was reduced from (mean +/- SE) 108 +/- 3 mmHg at baseline to 101 +/- 2 in average during treatment in the lisinopril group and from 105 +/- 2 to 103 +/- 2 in the nisoldipine group (P = 0.06 comparing changes in the two groups). Albuminuria was reduced 47% (95% CI 21-65) in the lisinopril group versus an increase of 11% (-3 to 27) in the nisoldipine group (P = 0.001). Fractional albumin clearance was reduced 37% (95% CI 4-59%) in the lisinopril versus an increase of 35% (8-69%) in the nisoldipine group (P < 0.01). GFR decreased from 85 +/- 5 ml x min(-1) x 1.73 m(-2) to 73 +/- 5 in the lisinopril group and from 84 +/- 6 to 80 +/- 7 in the nisoldipine group (P < 0.05). The effect of study medication on albuminuria and GFR was independent of changes in systemic blood pressure and baseline variables in multiple regression analyses. In summary, lisinopril reduced albuminuria, but also GFR, to a greater extent than did nisoldipine in hypertensive IDDM patients with diabetic nephropathy during the 1st year of treatment. Longer follow-up is required to clarify whether these drugs have different renoprotective effects.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. Andersen, P. Jacobsen, L. Tarnow, P. Rossing, T. R. Juhl, and H.-H. Parving Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy Nephrol. Dial. Transplant., February 1, 2003; 18(2): 293 - 297. [Abstract] [Full Text] [PDF]

				C. Arauz-Pacheco, M. A. Parrott, and P. Raskin The Treatment of Hypertension in Adult Patients With Diabetes Diabetes Care, January 1, 2002; 25(1): 134 - 147. [Full Text] [PDF]

				H. Herlitz, K. Harris, T. Risler, G. Boner, J. Bernheim, J. Chanard, and M. Aurell The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study Nephrol. Dial. Transplant., November 1, 2001; 16(11): 2158 - 2165. [Abstract] [Full Text] [PDF]

				H. Buter, G. Navis, R. P. F. Dullaart, D. de Zeeuw, and P. E. de Jong Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM Nephrol. Dial. Transplant., April 1, 2001; 16(4): 771 - 775. [Abstract] [Full Text] [PDF]

				I. Golovchenko, M. L. Goalstone, P. Watson, M. Brownlee, and B. Draznin Hyperinsulinemia Enhances Transcriptional Activity of Nuclear Factor-{kappa}B Induced by Angiotensin II, Hyperglycemia, and Advanced Glycosylation End Products in Vascular Smooth Muscle Cells Circ. Res., October 27, 2000; 87(9): 746 - 752. [Abstract] [Full Text] [PDF]

				B. Nielsen and A. Flyvbjerg Calcium channel blockers - the effect on renal changes in clinical and experimental diabetes: an overview Nephrol. Dial. Transplant., May 1, 2000; 15(5): 581 - 585. [Full Text] [PDF]

				M. A. Moore, M. Epstein, L. Agodoa, and L. D. Dworkin Current Strategies for Management of Hypertensive Renal Disease Arch Intern Med, January 11, 1999; 159(1): 23 - 28. [Abstract] [Full Text] [PDF]